Loading...

IBRX IMMUNITYBIO INC US FDA Inspections 8-K Filing

MMNT

BRX

IMMUNITYBIO INC

(IBRX)

2025 8-K

Revenue Agreement Update

Financial Results Update

Regulatory Approval

Convertible Note Amendment

Financial Results Update

Regulatory Approval

Stock Issuance Update

Board Appointment

Regulatory Update

Financial Update

Equity Offerings

Management Changes

Financial Statements

Regulatory Compliance

Financial Update

Executive Compensation

Director Resignation

Public Offering

Study Data Release

Annual Meeting of Stockholders

Quantitative Data

Bonuses and Incentive Awards

Quantitative Data in Filing

Quantitative Data

Financial Agreement and Ann...

Other Special Situation

Quantitative Data

Quantitative Data

Stock Purchase Agreement

Financial Update

Quantitative Data

External Links:

ImmunityBio, Inc. announced on May 5, 2025, that the FDA issued a refusal to file letter regarding its supplemental biologics license application for ANKTIVA plus BCG aimed at treating a specific type of bladder cancer.

AI Assistant

IMMUNITYBIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.